

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Shasun Pharmaceuticals Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Sequent Scientific Limited PACs: Ambematha Securities K R Ravishankar Triumph Venture Holdings LLP		
Whether the acquirer belongs to Promoter/ Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	Bombay Stock Exchange Limited / National Stock Exchange of India Limited		
Details of the acquisition/ disposal-as follows	Number	% w.r.t. total share/ voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC(**)
<u>Before the acquisition/ Sale-under consideration, holding of:</u>			
a) Shares carrying voting rights	5,123,313	8.52	7.62
b) Shares in the nature of encumbrance (pledge/ lien/ non – disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	7,100,000	-	10.56
Total (a+b+c+d)	12,223,313	8.52	18.18
<u>Details of acquisition/sale</u>			
a) Shares carrying voting rights acquired/ sold- (On Conversion of 71,00,000 warrants)	7,100,000	10.56	10.56
b) VRs acquired /sold otherwise than by shares	-	-	-
c) Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
d) Shares encumbered/ invoked/ released by the acquirer	-	-	-
Total (a+b+c+/-d)	7,100,000	10.56	10.56



Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

After the acquisition/sale, holding of:			
a) Shares carrying voting rights	12,223,313	18.18	18.18
b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by shares	-	-	-
d) Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition.	-	-	-
Total (a+b+c+d)	12,223,313	18.18	18.18
Mode of acquisition / sale—(e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Conversion of 7,100,000 warrants into equivalent number of equity shares		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	June 8, 2015		
Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs. 120,247,704 (60,123,852 shares of Rs.2/- each)		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	Rs. 134,447,704 (67,223,852 shares of Rs.2/- each)		
Total diluted share/voting capital of the TC after the said acquisition/sale.	Rs. 134,447,704 (67,223,852 shares of Rs. 2/- each)		

(*) Total share capital/ voting capital to be taken as per latest filing done by the Company to the Stock Exchange under Clause 35 of the Listing Agreement.

(**) Diluted share/ voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/ warrants into equity shares of the TC.

Place: Bangalore
Date: June 9, 2015

For Sequent Scientific Limited




Preetham Hebbar
 Company Secretary